These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26131914)

  • 1. The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome.
    Dori N; Green T; Weizman A; Gothelf D
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):83-90. PubMed ID: 26131914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review.
    Mosheva M; Korotkin L; Gur RE; Weizman A; Gothelf D
    Eur Child Adolesc Psychiatry; 2020 Aug; 29(8):1035-1048. PubMed ID: 30949827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of clozapine in treatment-resistant psychotic patients with DiGeorge syndrome (22q11.2 deletion syndrome): a case series.
    Berardelli I; Cifrodelli M; Giuliani C; Antonelli G; Putotto C; Pulvirenti F; Pompili M
    Int Clin Psychopharmacol; 2024 Jul; 39(4):284-287. PubMed ID: 37824335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and tolerability of pharmacotherapy for psychosis in 22q11.2 Deletion Syndrome: A systematic review.
    Tanham M; Chen R; Warren N; Heussler H; Scott JG
    Aust N Z J Psychiatry; 2024 May; 58(5):393-403. PubMed ID: 38383990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial.
    Green T; Steingart L; Frisch A; Zarchi O; Weizman A; Gothelf D
    J Neural Transm (Vienna); 2012 Nov; 119(11):1417-23. PubMed ID: 22678699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review.
    de Boer J; Boot E; van Gils L; van Amelsvoort T; Zinkstok J
    Am J Med Genet A; 2019 Nov; 179(11):2292-2306. PubMed ID: 31407842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudinal 2-site study.
    Gothelf D; Schneider M; Green T; Debbané M; Frisch A; Glaser B; Zilkha H; Schaer M; Weizman A; Eliez S
    J Am Acad Child Adolesc Psychiatry; 2013 Nov; 52(11):1192-1203.e3. PubMed ID: 24157393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dimensional structure of psychopathology in 22q11.2 Deletion Syndrome.
    Niarchou M; Moore TM; Tang SX; Calkins ME; McDonald-McGuinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
    J Psychiatr Res; 2017 Sep; 92():124-131. PubMed ID: 28433949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome.
    Basel D; Mosheva M; Maeder J; Schneider M; Shani S; Weinberger R; Eliez S; Gothelf D
    Eur Child Adolesc Psychiatry; 2022 Sep; 31(9):1367-1375. PubMed ID: 33871687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Antipsychotic Medication Use in Autism Spectrum Disorder.
    Wink LK; Pedapati EV; Horn PS; McDougle CJ; Erickson CA
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):91-94. PubMed ID: 26465194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predominant negative symptoms in 22q11.2 deletion syndrome and their associations with cognitive functioning and functional outcome.
    Schneider M; Van der Linden M; Menghetti S; Glaser B; Debbané M; Eliez S
    J Psychiatr Res; 2014 Jan; 48(1):86-93. PubMed ID: 24189154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome.
    Monks S; Niarchou M; Davies AR; Walters JT; Williams N; Owen MJ; van den Bree MB; Murphy KC
    Schizophr Res; 2014 Mar; 153(1-3):231-6. PubMed ID: 24534796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D deficiency, behavioral atypicality, anxiety and depression in children with chromosome 22q11.2 deletion syndrome.
    Kelley L; Sanders AF; Beaton EA
    J Dev Orig Health Dis; 2016 Dec; 7(6):616-625. PubMed ID: 27827293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White matter microstructural abnormalities of the cingulum bundle in youths with 22q11.2 deletion syndrome: associations with medication, neuropsychological function, and prodromal symptoms of psychosis.
    Kates WR; Olszewski AK; Gnirke MH; Kikinis Z; Nelson J; Antshel KM; Fremont W; Radoeva PD; Middleton FA; Shenton ME; Coman IL
    Schizophr Res; 2015 Jan; 161(1):76-84. PubMed ID: 25066496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hippocampi of children with chromosome 22q11.2 deletion syndrome have localized anterior alterations that predict severity of anxiety.
    Scott JA; Goodrich-Hunsaker N; Kalish K; Lee A; Hunsaker MR; Schumann CM; Carmichael OT; Simon TJ
    J Psychiatry Neurosci; 2016 Apr; 41(3):203-13. PubMed ID: 26599134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Premorbid adjustment and schizophrenia in individuals with 22q11.2 deletion syndrome.
    Yuen T; Chow EW; Silversides CK; Bassett AS
    Schizophr Res; 2013 Dec; 151(1-3):221-5. PubMed ID: 24262682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to clozapine in a clinically identifiable subtype of schizophrenia.
    Butcher NJ; Fung WL; Fitzpatrick L; Guna A; Andrade DM; Lang AE; Chow EW; Bassett AS
    Br J Psychiatry; 2015 Jun; 206(6):484-91. PubMed ID: 25745132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
    Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
    Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental trajectories in 22q11.2 deletion.
    Swillen A; McDonald-McGinn D
    Am J Med Genet C Semin Med Genet; 2015 Jun; 169(2):172-81. PubMed ID: 25989227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.